Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 3/20 | 0.43 |
| ▸ | MAP4K1 | Q92918 | 4/20 | 0.41 |
| ▸ | MAP4K3 | Q8IVH8 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 5/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 5/20 | 0.38 |
| ▸ | WNT1 | P04628 | 4/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.36 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.36 |
| ▸ | BRAF | P15056 | 1/20 | 0.36 |
| ▸ | TYRO3 | Q06418 | 2/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13336186 | 0.96 | MAP4K1 (0.42) | GRM2MAP4K1MAP4K3GSK3BDYRK1A | |
| SCHEMBL13336147 | 0.91 | GRM2 (0.44) | GRM2MAP4K1MAP4K3GSK3BDYRK1A | |
| SCHEMBL13336034 | 0.90 | MAP4K1 (0.42) | MAP4K1MAP4K3GSK3BDYRK1AWNT1 | |
| SCHEMBL13336031 | 0.89 | MAP4K1 (0.42) | MAP4K1MAP4K3GSK3BDYRK1AWNT1 | |
| SCHEMBL13335984 | 0.86 | MAP4K1 (0.45) | MAP4K1MAP4K3GSK3BDYRK1AWNT1 | |
| SCHEMBL13336322 | 0.86 | GRM2 (0.42) | GRM2MAP4K1MAP4K3GSK3BDYRK1A | |
| SCHEMBL13336181 | 0.85 | GRM2 (0.43) | GRM2MAP4K1MAP4K3GSK3BDYRK1A | |
| SCHEMBL1571563 | 0.85 | WNT1 (0.40) | GRM2MAP4K1MAP4K3GSK3BDYRK1A | |
| SCHEMBL13336165 | 0.85 | GRM2 (0.41) | GRM2MAP4K1MAP4K3GSK3BDYRK1A | |
| SCHEMBL13336180 | 0.84 | MAP4K1 (0.44) | GRM2MAP4K1MAP4K3GSK3BDYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100121052-A1 | Novel compounds for treating proliferative diseases | JAIN RAMA | 2010-05-13 | — | — | US | disclosed |
| US-20100121052-A1 | Novel compounds for treating proliferative diseases | JAIN RAMA | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100121052-A1 | Novel compounds for treating proliferative diseases | PDK1, PDK2, PDK3 | GRM2 2795/4885MAP4K1 112/4885MAP4K3 103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.